A 150-child trial found an FDA-cleared ADHD stimulation device did not significantly reduce symptoms, raising concerns over ...

The randomized, double-blind, sham-controlled trial evaluated 56 adults with ADHD who received four weeks of Nexalin’s ...

For most, the idea that you might don a headset to zap your depression away or use electromagnetic pulses to sharpen your cognition seems better placed in a science fiction novel from the 1930s than ...

HOUSTON, TX, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, ...

NEW YORK, July 31, 2024 /PRNewswire/ -- The global neurostimulation devices market size is estimated to grow by USD 6.26 billion from 2023-2027, according to Technavio. The market is estimated to grow ...

HOUSTON, TEXAS, March 14, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NXL) (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that it has commenced sales of its second generation ...

Nia Therapeutics announced the publication of the first in vivo validation of its wireless, implantable brain-computer ...

Shares of Nexalin Technology nearly doubled after the company said its second-generation Sync neurostimulation device can improve cognitive performance and enhance brain network connectivity in ...

For many people living with multiple sclerosis (MS), walking can become one of the most challenging daily tasks. As many as 3 in 4 people with MS have gait issues caused by factors like loss of muscle ...

COSTA MESA, Calif., Oct. 21, 2025 /PRNewswire/ -- Amid record-high drug overdose rates and no FDA-approved medications for stimulant addiction, a new peer-reviewed study published in Frontiers in ...